Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-01-17
2006-01-17
Wilson, Michael C. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093200, C424S093210
Reexamination Certificate
active
06987096
ABSTRACT:
The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.
REFERENCES:
patent: 5821081 (1998-10-01), Boyd et al.
patent: WO 93/06216 (1993-04-01), None
Abuchowski et al., “Soluble Polymer-Enzyme Adducts,”in Enzymes as Drugs, Holcenberg et al., eds., John Wiley: New York, 1981, pp. 367-383.
Abuchowski et al., Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol,Journal of Biological Chemistry, 252(11), 3578-3581 (1977).
Aullo et al., “A Recombinant Diphtheria Toxin Related Human CD4 Fusion Protein Specifically Kills HIV Infected Cells Which Express gp120 But Selects Fusion Toxin Resistant Cells Which Carry HIV,”EMBO Journal, 11(2), 575-583 (1992).
Balter, “UN Readies New Global AIDS Plan,”Science, 266, 1312-1313 (1994).
Banga et al., “Systemic Delivery of Therapeutic Peptides and Proteins,”International Journal of Pharmaceutics, 48, 15-50 (1988).
Barry, “The Transdermal Route for the Delivery of Peptides and Proteins,”in Delivery Systems for Peptide Drugs, Davis et al., eds., Plenum Press: New York, 1986, pp. 265-275.
Berzofsky, “Approaches and Issues in the Development of Vaccines Against HIV,”Journal of Acquired Immune Deficiency Syndromes, 4, 451-459 (1991).
Bird, “The Use of Spermicide Containing Nonoxynol-9 in the Prevention of HIV Infection,”AIDS, 5(7), 791-796 (1991).
Bourinbaiar et al., “Anti-HIV Effect of Gramicidin In Vitro: Potential for Spermicide Use,”Life Sciences, 54(1), 5-9 (1994).
Bourinbaiar et al., “Comparative In Vitro Study of Contraceptive Agents with Anti-HIV Activity: Gramicidin, Nonoxynol-9, and Gossypol,”Contraception, 49, 131-137 (1994).
Boyd, “Strategies for the Identification of New Agents for the Treatment of AIDS: A National Program to Facilitate the Discovery and Preclinical Development of New Drug Candidates for Clinical Evaluation,”AIDS Etiology, Diagnosis, Tretment, and Prevention, Second Edition, DeVita et al., eds., J.B. Lippincott Company, 1988, pp. 305-317.
Boyd et al., “Anti-HIV Michellamines fromAncistrocladus korupensis,” Journal of Medicinal Chemistry, 37(12), 1740-1745 (1994).
Capon et al., “Designing CD4 Immunoadhesins for AIDS Therapy,”Nature, 337, 525-531 (1989).
Capon et al., “The CD4-gp120 Interaction and AIDS Pathogenesis,”Annu. Rev. Immunol., 9, 649-678 (1991).
Carone et al., “Renal Tubular Processing of Small Peptide Hormones,”The Journal of Laboratory and Clinical Medicine, 100(1), 1-14 (1982).
Carter et al., “Structure of Majusculamide C, a Cyclic Depsipeptide fromLyngbya majuscula,” J. Org. Chem., 49, 236-241 (1984).
Chaudhary et al., “Selective Killing of HIV-Infected Cells by Recombinant Human CD4-PseudomonasExotoxin Hybrid Protein,”Nature, 335, 369-372 (1988).
Chaudhary et al., “CD4-PE4O—A Chimeric Toxin Active Against Human Immunodeficiency Virus (HIV) -Infected Cells,”The Human Retroviruses, pp. 379-387.
Coffin, John M., “HIV Population Dynamics In Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy,”Science, 267, 483-489 (1995).
Cohen, “High Turnover of HIV in Blood Revealed by New Studies,”Science, 267, 179 (1995).
Coll et al., “The Application of Vacuum Liquid Chromatograph to the Separation of Terpene Mixtures,”Journal of Natural Products, 49(5), 934-936 (1986).
Davey et al., “Use of Recombinant Soluble CD4PseudomonasExotoxin, a Novel Immunotoxin, for Treatment of Persons Infected with Human Immunodeficiency Virus,”Journal of Infectious Diseases, 170, 1180-1188 (1994).
Davis, “Delivery Systems for Bipharmaceuticals,”J. Pharm. Pharmacol., 44(Suppl. 1), 186-190 (1992).
De Clercq, “Antiviral Agents: Characteristic Activity Spectrum Depending on the Molecular Target with Which They Interact,”Advances In Virus Research, 42, 1-55 (1993).
De Clercq, “Basic Approaches to Anti-Retroviral Treatment,”Journal of Acquired Immune Deficiency Syndromes, 4(3), 207-218 (1991).
Deasy et al.,in Microencapsulation and Related Processes, Swarbrick J., ed., Marcel Dekker, Inc.: New York, 1984, pp. 1-60.
Emtage, “Biotechnology and Protein Production,”in Delivery Systems for Peptide Drugs, Davis et al., eds., Plenum Press: New York, 1986, pp. 23-33.
Eppstein et al., “Alternative Delivery Systems for Peptides and Proteins as Drugs,”CRC Critical Reviews in Therapeutic Drug Carrier Systems, 5(2), 99-139 (1988).
Faulkner, “Marine Natural Products,”Natural Product Reports, pp. 355-394 (1994).
Frankmölle et al., “Antifungal Cyclic Peptides from the Terrestrial Blue-Green AlgaAnabaena laxa,” The Journal of Antibiotics, 45(9), 1451-1457 (1992).
Freed et al., “The Role of the HIV Envelope Glycoproteins in Cell Fusion and the Pathogenesis of AIDS,”Bull. Inst. Pasteur, 88, 73-110 (1990).
Glombitza et al.,in Algal and Cynobacterial Biotechnology, Cresswell, R.C., et al., eds., 1989, pp. 211-218.
Gulakowski et al., “A Semiautomated Multiparameter Approach for Anti-HIV Drug Screening,”Journal of Virological Methods, 33, 87-100 (1991).
Gustafson et al., “A Nonpromoting Phorbol from the Samoan Medicinal PlantHomalanthus nutansInhibits Cell Killing by HIV-1,”J. Med. Chem., 35, 1978-1986 (1982).
Guyden, “Techniques for Gene Cloning and Expression,”in Recombinant DNA Technology Concepts and Biomedical Applications, Steinberg et al., eds., Prentice Hall: Englewood Cliffs, NJ, 1993, pp. 81-124 and 150-162.
Husson et al., “Phase 1 Study of Continuous-Infusion Soluble CD4 as a Single Agent and In Combination with Oral Dideoxyinosine Therapy in Children with Symptomatic Human Immunodeficiency Virus Infection,”The Journal of Pediatrics, 121(4), 627-633 (1992).
Kashman et al., “The Calanolides, a Novel HIV-Inhibitory Class of Coumarin Derivatives from the Tropical Rainforest Tree,Calophyllum lanigerum,” Journal of Medicinal Chemistry, 35(15), 2735-2743 (1992).
Koenig et al., “Selective Infection of Human CD4+ Cells by Simian Immunodeficiency Virus: Productive Infection Associated with Envelope Glycoprotein-Induced Fusion,”Proc. Natl. Acad. Sci. USA, 86, 2443-2447 (1989).
Krishnamurthy et al., “Structural Characterization of Toxic Cyclic Peptides from Blue-Green Algae by Tandem Mass Spectrometry,”Proc. Natl. Acad. Sci. USA, 86, 770-774 (1989).
Laemmli, “Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4,”Nature, 227, 680-685 (1970).
Langner, “Antiviral Effects of Different CD4-Immunoglobulin Constructs Against HIV-1 and SIV: Immunological Characterization, Pharmacokinetic Data and In Vivo Experiments,”Arch. Virol., 130, 157-170 (1993).
Lin et al., “Selective Inhibition of Human Immunodeficiency Virus Type 1 Replication by the (−) but Not the (+) Enantiomer of Gossypol,”Animicrob. Agents Chemother., 33(12), 2149-2151 (1989).
Lipton, “HIV Displays Its Coat of Arms,”Nature, 367, 113-114 (1994).
Lisi et al., “Enzyme Therapy: I. Polyethylene Glycol:β-Glucuronidase Conjugates as Potential Therapeutic Agents in Acid Mucopolysaccharidosis,”J. Appl. Biochem., 4, 19-33 (1982).
Matsushita et al., “Characterization of a Human Immunodeficiency Virus Neutralizing Monoclonal Antibody and Mapping of the Neutralizing Epitope,”Journal of Virology, 62(6), 2107-2114 (1988).
Maulding, “Prolonged Delivery of Peptides by Microcapsules,”Journal of Controlled Release, 6, 167-176 (1987).
McCaffrey et al., “A Rapid Flu
Boyd Michael R.
Gustafson Kirk R.
McMahon James B.
Shoemaker Robert H.
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
Wilson Michael C.
LandOfFree
Antiviral proteins and peptides, DNA coding sequences... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral proteins and peptides, DNA coding sequences..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral proteins and peptides, DNA coding sequences... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3526445